Feasibility and benefit of hydroxycarbamide as a long-term treatment for sickle cell disease patients: results from the North West London Sickle Cell Disease Registry

Am J Hematol. 2011 Nov;86(11):958-61. doi: 10.1002/ajh.22146. Epub 2011 Sep 21.

Authors

Annette Gilmore¹, Gavin Cho, Jo Howard, Mark Layton, Michele Afif, Robert George Hughes, Nicola J Philpott, Sameer Patankar, Sally C Davies; North West London Haemoglobinopathy Registry Group

Collaborators

North West London Haemoglobinopathy Registry Group:
Shubha Allard, Gail Abrahamson, Colin A Michie, Cathy Rose, Inderjeet Dokal, Anne E M Davies, Mallika Sekhar

Affiliation

¹ Department of Haematology, Central Middlesex Hospital, London, United Kingdom. annette.gilmore@nhs.net

PMID: 21948113
DOI: 10.1002/ajh.22146

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Chest Syndrome / complications
Acute Chest Syndrome / mortality
Acute Chest Syndrome / pathology
Acute Chest Syndrome / therapy*
Adolescent
Adult
Anemia, Sickle Cell / complications
Anemia, Sickle Cell / mortality
Anemia, Sickle Cell / pathology
Anemia, Sickle Cell / therapy*
Blood Transfusion
Child
Child, Preschool
Drug Dosage Calculations
Erythrocyte Indices
Female
Fetal Hemoglobin / analysis
Humans
Hydroxyurea / administration & dosage
Hydroxyurea / adverse effects
Hydroxyurea / therapeutic use*
London
Longitudinal Studies
Male
Registries
Survival Rate

Substances

Fetal Hemoglobin
Hydroxyurea